InVivo Therapeutics Announces Late-Breaking Oral Presentation at the 2016 Congress of Neurological Surgeons Annual Meeting
September 20 2016 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced that Michael Fehlings, M.D., Ph.D., Director of the
Spinal Program at the Krembil Neuroscience Centre of Toronto
Western Hospital and a Professor of Neurosurgery at the University
of Toronto, will give a late-breaking oral presentation titled
“Clinical-Pathological Assessment of Severe (AIS A) Traumatic Acute
Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy Observations
from the INSPIRE Trial” at the 2016 Congress of Neurological
Surgeons (CNS) Annual Meeting on September 28, 2016. The abstract
was one of the top three late-breaking abstracts chosen for an oral
presentation.
“INSPIRE has provided new insights into acute spinal cord injury
pathology, allowing for the application of the Neuro-Spinal
ScaffoldTM as a potential new treatment modality for complete
spinal cord injury. I’m looking forward to sharing the findings
with the neurosurgical community,” Dr. Fehlings said.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said
“We are delighted that important scientific observations being made
in the INSPIRE study were selected for late-breaking oral
presentation at a prestigious neurosurgical conference and that one
of the leaders in the field of spinal cord injury treatment and
research is making the presentation.”
As previously announced, Nicholas Theodore, M.D., Director of
the John Hopkins Neurosurgical Spine Center, will be giving an oral
platform presentation; Robert Heary, M.D., Director of the Spine
Center at Rutgers New Jersey Medical School will be giving a poster
presentation; and the company will have a steering committee
meeting and exhibitor booth.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the
biodegradable Neuro-Spinal Scaffold within the decompressed and
debrided injury epicenter is intended to support appositional
healing, thereby reducing post-traumatic cavity formation, sparing
white matter, and allowing neural regeneration across the healed
wound epicenter. The Neuro-Spinal Scaffold, an investigational
device, has received a Humanitarian Use Device (HUD) designation
and currently is being evaluated in the INSPIRE pivotal probable
benefit study for the treatment of patients with complete (AIS A)
traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160920005156/en/
InVivo TherapeuticsBrian Luque, 617-863-5535Investor
Relationsbluque@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024